Plea To FDA: Set Realistic Bar For New Breast Cancer Trial Endpoint

Commenting on FDA’s draft guidance for accelerated approval using a relatively new surrogate marker of pathologic complete response, Roche/Genentech is wary that FDA may expect too high a bar for results. BIO asks FDA to consider safety when evaluating “magnitude of benefit.”